Evidence map›Paper›PMID 37950903›Full record

ArticleThe oncologist2024

Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).

Yosuke Kito, Hisato Kawakami, Seiichiro Mitani, Shinichi Nishina, Toshihiko Matsumoto, Takao Tsuzuki, Yudai Shinohara, Hozumi Shimokawa, Ryosuke Kumanishi, Takashi Ohta and 9 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 15 institutions in 1 country.

Yosuke KitoDepartment of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.ORCID 0000-0003-3677-9880
Hisato KawakamiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.ORCID 0000-0002-3280-4850
Seiichiro MitaniDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
Shinichi NishinaDepartment of Medical Oncology, Kurashiki Central Hospital, Okayama, Japan.
Toshihiko MatsumotoDepartment of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan.
Takao TsuzukiDepartment of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
Yudai ShinoharaDepartment of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
Hozumi ShimokawaDepartment of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.
Ryosuke KumanishiDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Takashi OhtaDepartment of Clinical Oncology, Kansai Rosai Hospital, Hyogo, Japan.
Hiroo KatsuyaDivision of Hematology, Respiratory Medicine, and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Takeshi KawakamiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Tomohiro NishinaDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Hiroko HasegawaDepartment of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Kohei AkiyoshiDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Yasutaka ChibaClinical Research Center, Kindai University Hospital, Osaka, Japan.
Kentaro YamazakiDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Shuichi HironakaDepartment of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo, Japan.
Kei MuroDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Aichi Cancer Center · JPKindai University · JPKyushu Hospital · JPShizuoka Cancer Center · JPHimeji Red Cross Hospital · JPIshikawa Prefectural Central Hospital · JPKansai Rosai Hospital · JPKindai University Hospital · JPKobe City Medical Center General Hospital · JPKurashiki Central Hospital · JPKyorin University · JPOsaka City General Hospital · JPOsaka National Hospital · JPSaga University · JPShikoku Cancer Center · JP

Funding

Taiho Pharmaceutical Co., Ltd.
6 · The paper itself

Abstract

backgroundTrifluridine/tipiracil (FTD/TPI) plus bevacizumab has shown clinical benefit for metastatic colorectal cancer (mCRC) refractory to standard therapy. However, few data have been available for patients with pretreated mCRC who are intolerant of intensive therapy (vulnerable).

methodsWe performed a multicenter retrospective study (WJOG14520G; TWILIGHT) of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC. Eligibility criteria included previous chemotherapy (although patients treated with all key cytotoxic agents, a fluoropyrimidine, oxaliplatin, and irinotecan, were excluded) and intolerance of full-dose combination therapy with oxaliplatin or irinotecan at the start of FTD/TPI plus bevacizumab.

resultsThe median age of 93 evaluable patients was 79 years (range, 21-90). Intolerance of intensive therapy was attributable to an older age in 60 (65%) patients, serious concomitant disease in 24 (26%) patients, and a poor performance status in 19 (20%) patients. FTD/TPI plus bevacizumab was administered as second-line treatment in 74 (80%) patients and as third- or fourth-line treatment in 19 (20%) patients. The objective response rate was 4.9% (95% confidence interval [CI], 1.4%-12.2%), and the disease control rate was 67.9% (95% CI, 56.6%-77.8%). With a median follow-up time of 21.6 months, median overall survival and progression-free survival were 18.6 months (95% CI, 12.1-23.2) and 6.3 months (95% CI, 5.0-8.3), respectively. Neutropenia of grade ≥3 developed in 50 (54%) patients, whereas 2 (2%) patients experienced febrile neutropenia, and no treatment-related death was observed.

conclusionOur data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsFrontotemporal DementiaPyrrolidinesRectal NeoplasmsThymineAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug CombinationsHumansIrinotecanMiddle AgedOxaliplatinBevacizumabDrug CombinationsIrinotecanOxaliplatinPyrrolidinesThyminetipiracilTrifluridineUracilbevacizumabintensive therapymetastatic colorectal cancertrifluridine/tipiracilvulnerable patients

Identifiers

PMID37950903
PMCPMC10911898
OpenAlexW4388586210

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.